WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (NASDAQ:NURO) today reported the commercial launch of
DPNCheck in Mexico. The initial DPNCheck order will be utilized by one
of Mexico's six major government healthcare institutions to improve the
detection of diabetic neuropathy and advance the overall management of
diabetes in their patient population.
Mexico has one of the highest rates of type 2 diabetes in the world with
nearly 12% of the adult population diagnosed. The disease results in
70,000 deaths per year making diabetes the leading cause of death for
the country. The prevalence of diabetes is projected to continue to
increase in the coming years.
Scienta Farma, S.A. de C.V. distributes DPNCheck for NeuroMetrix in
Mexico. The largest market opportunity for DPNCheck is within the six
public institutions that provide healthcare services to the majority of
Mexico's 120 million citizens. Scienta Farma focuses their marketing and
sales efforts on gaining government contracts with these institutions.
"Mexico is a very important component of our international strategy for
DPNCheck and we believe this initial sale will help accelerate Scienta
Farma's efforts to expand DPNCheck adoption within the other major
government healthcare institutions," said Michael MacDonald, NeuroMetrix
SVP of Commercial Operations.
"DPNCheck is a significant clinical advance for the care of diabetic
patients in Mexico," said Alberto Elias Fernandez, Executive Vice
President of Scienta Farma. "We are excited to be partnering with
NeuroMetrix to bring this important technology to clinicians in Mexico."
About DPNCheck
DPNCheck is a quantitative nerve conduction test that is used by
physicians and health care professionals to evaluate systemic
neuropathies such as diabetic peripheral neuropathy, or DPN. It is
designed to be used at the point-of-care to objectively detect, stage,
and monitor DPN. The device measures nerve conduction velocity and
response amplitude of the sural nerve, a nerve in the lower leg and
ankle. These parameters are recognized as sensitive and specific
biomarkers of DPN.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151229005122/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
